[开放获取]    中国反常性痤疮/化脓性汗腺炎诊疗专家共识（2021版）

doi:10.35541/cjd.20200802

中华皮肤科杂志 ›› 2021, Vol. 54 ›› Issue (2): 97-104.doi: 10.35541/cjd.20200802

[开放获取] 中国反常性痤疮/化脓性汗腺炎诊疗专家共识（2021版）

中国反常性痤疮/化脓性汗腺炎诊疗专家共识制订小组

中国反常性痤疮/化脓性汗腺炎诊疗专家共识制订小组

收稿日期:2020-08-14 修回日期:2020-12-20 发布日期:2021-01-29
通讯作者: 王宝玺 E-mail:wangbx@vip.126.com

Diagnosis and treatment of acne inversa/hidradenitis suppurativa in China: an expert consensus statement （2021 version）

Consensus Writing Group on the Diagnosis and Treatment of Acne Inversa/Hidradenitis Suppurativa in China

Consensus Writing Group on the Diagnosis and Treatment of Acne Inversa/Hidradenitis Suppurativa in China

Received:2020-08-14 Revised:2020-12-20 Published:2021-01-29
Contact: Wang Baoxi E-mail:wangbx@vip.126.com

摘要/Abstract

摘要： 【摘要】反常性痤疮（AI）/化脓性汗腺炎（HS）是一种因毛囊闭锁导致毛囊皮脂腺单位受累的慢性复发性炎症性皮肤病，好发于顶泌汗腺分布区域，主要表现为青春期开始出现的疼痛性、深在性、炎症性皮损。AI/HS发病与遗传、炎症与免疫、微生物、肥胖及吸烟等因素相关。AI/HS治疗困难，目前的治疗以控制皮损发作频率和发作持续时间、提高患者生活质量为主。医生应根据病情严重程度分级治疗，药物治疗包括抗生素、维A酸类、生物制剂、免疫抑制剂以及抗雄激素药物等，辅助治疗包括外科手术或光电治疗。该共识旨在进一步规范中国AI/HS诊断与治疗方法，提高诊疗水平。

关键词: 化脓性汗腺炎, 反常性痤疮, 诊断, 治疗, 共识

Abstract: 【Abstract】 Acne inversa （AI）/hidradenitis suppurativa （HS） is a chronic, recurrent, inflammatory skin disease that centers on the hair follicular unit because of follicular occlusion. It mainly presents as painful, deep-seated, inflamed lesions since puberty, and most commonly occurs in the apocrine gland-bearing areas. The etiology and pathogenesis of AI/HS involve internal and external factors, such as genetic susceptibility, inflammation and immunity, microorganisms, obesity and smoking. Treatment of AI/HS is difficult, and the current aim of treatment is to control the frequency and duration of disease flares and improve the quality of life. Treatment protocols of AI/HS should be based on the disease severity grade. Medical treatments include antibiotics, retinoids, biologics, immunosuppressive agents, antiandrogen agents, and so on, and adjuvant treatments include surgery and laser/light therapies. This consensus aims to further standardize the diagnosis and treatment procedures of AI/HS in China, so as to facilitate its diagnosis and treatment.

Key words: Hidradenitis suppurativa, Acne inversa, Diagnosis, Therapy, Consensus

中国反常性痤疮/化脓性汗腺炎诊疗专家共识制订小组. [开放获取] 中国反常性痤疮/化脓性汗腺炎诊疗专家共识（2021版）[J]. 中华皮肤科杂志, 2021,54(2):97-104. doi:10.35541/cjd.20200802

Consensus Writing Group on the Diagnosis and Treatment of Acne Inversa/Hidradenitis Suppurativa in China. Diagnosis and treatment of acne inversa/hidradenitis suppurativa in China: an expert consensus statement （2021 version）[J]. Chinese Journal of Dermatology, 2021, 54(2): 97-104.doi:10.35541/cjd.20200802

参考文献 57

［1］	Cosmatos I, Matcho A, Weinstein R, et al. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States［J］. J Am Acad Dermatol, 2013,68（3）:412⁃419. doi: 10.1016/j.jaad.2012.07.027.
［2］	Jemec GB, Kimball AB. Hidradenitis suppurativa: epidemiology and scope of the problem［J］. J Am Acad Dermatol, 2015,73（5 Suppl 1）:S4⁃S7. doi: 10.1016/j.jaad.2015.07.052.
［3］	Vinding GR, Miller IM, Zarchi K, et al. The prevalence of inverse recurrent suppuration: a population⁃based study of possible hidradenitis suppurativa［J］. Br J Dermatol, 2014,170（4）:884⁃889. doi: 10.1111/bjd.12787.
［4］	Garg A, Kirby JS, Lavian J, et al. Sex⁃ and age⁃adjusted population analysis of prevalence estimates for hidradenitis suppurativa in the United States［J］. JAMA Dermatol, 2017,153（8）:760⁃764. doi: 10.1001/jamadermatol.2017.0201.
［5］	Napolitano M, Megna M, Timoshchuk EA, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment［J］. Clin Cosmet Investig Dermatol, 2017,10:105⁃115. doi: 10.2147/CCID.S111019.
［6］	Lee JH, Kwon HS, Jung HM, et al. Prevalence and comorbidities associated with hidradenitis suppurativa in Korea: a nationwide population⁃based study［J］. J Eur Acad Dermatol Venereol, 2018,32（10）:1784⁃1790. doi: 10.1111/jdv.15071.
［7］	Yang JH, Moon J, Kye YC, et al. Demographic and clinical features of hidradenitis suppurativa in Korea［J］. J Dermatol, 2018,45（12）:1389⁃1395. doi: 10.1111/1346⁃8138.14656.
［8］	Kurokawa I, Hayashi N, Japan Acne Research Society. Questionnaire surveillance of hidradenitis suppurativa in Japan［J］. J Dermatol, 2015,42（7）:747⁃749. doi: 10.1111/1346⁃8138. 12881.
［9］	Wang B, Yang W, Wen W, et al. Gamma⁃secretase gene mutations in familial acne inversa［J］. Science, 2010,330（6007）:1065. doi: 10.1126/science.1196284.
［10］	Pink AE, Simpson MA, Desai N, et al. γ⁃Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis［J］. J Invest Dermatol, 2013,133（3）:601⁃607. doi: 10.1038/jid. 2012.372.
［11］	He Y, Xu H, Li C, et al. Nicastrin/miR⁃30a⁃3p/RAB31 axis regulates keratinocyte differentiation by impairing EGFR signaling in familial acne inversa［J］. J Invest Dermatol, 2019,139（1）:124⁃134. doi: 10.1016/j.jid.2018.07.020.
［12］	Kelly G, Hughes R, McGarry T, et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa［J］. Br J Dermatol, 2015,173（6）:1431⁃1439. doi: 10. 1111/bjd.14075.
［13］	Witte⁃Händel E, Wolk K, Tsaousi A, et al. The IL⁃1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction［J］. J Invest Dermatol, 2019,139（6）:1294⁃1305. doi: 10.1016/j.jid.2018.11.018.
［14］	Thomi R, Cazzaniga S, Seyed Jafari SM, et al. Association of hidradenitis suppurativa with T helper 1/T helper 17 phenotypes: a semantic map analysis［J］. JAMA Dermatol, 2018,154（5）:592⁃595. doi: 10.1001/jamadermatol.2018.0141.
［15］	Hotz C, Boniotto M, Guguin A, et al. Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa［J］. J Invest Dermatol, 2016,136（9）:1768⁃1780. doi: 10.1016/j.jid.2016.04.036.
［16］	Xu H, He Y, Hui Y, et al. NCSTN mutations in hidradenitis suppurativa/acne inversa do not influence cytokine production by peripheral blood mononuclear cells［J］. Br J Dermatol, 2017,176（1）:277⁃279. doi: 10.1111/bjd.15076.
［17］	Byrd AS, Carmona⁃Rivera C, O′Neil LJ, et al. Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa［J］. Sci Transl Med, 2019,11（508）:eaav5908. doi: 10.1126/scitranslmed.aav5908.
［18］	Kanni T, Zenker O, Habel M, et al. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?［J］. Br J Dermatol, 2018,179（2）:413⁃419. doi: 10.1111/bjd.16428.
［19］	Giamarellos⁃Bourboulis EJ, Argyropoulou M, Kanni T, et al. Clinical efficacy of complement C5a inhibition by IFX⁃1 in hidradenitis suppurativa: an open⁃label single⁃arm trial in patients not eligible for adalimumab［J］. Br J Dermatol, 2020,183（1）:176⁃178. doi: 10.1111/bjd.18877.
［20］	Ring HC, Thorsen J, Saunte DM, et al. The follicular skin microbiome in patients with hidradenitis suppurativa and healthy controls［J］. JAMA Dermatol, 2017,153（9）:897⁃905. doi: 10.1001/jamadermatol.2017.0904.
［21］	Ring HC, Bay L, Nilsson M, et al. Bacterial biofilm in chronic lesions of hidradenitis suppurativa［J］. Br J Dermatol, 2017,176（4）:993⁃1000. doi: 10.1111/bjd.15007.
［22］	Ring HC, Emtestam L. The microbiology of hidradenitis suppurativa［J］. Dermatol Clin, 2016,34（1）:29⁃35. doi: 10.1016/j.det.2015.08.010.
［23］	Lyons AB, Shabeeb N, Nicholson CL, et al. Emerging medical treatments for hidradenitis suppurativa［J］. J Am Acad Dermatol, 2020,83（2）:554⁃562. doi: 10.1016/j.jaad.2020.04.009.
［24］	Nazary M, van der Zee HH, Prens EP, et al. Pathogenesis and pharmacotherapy of hidradenitis suppurativa［J］. Eur J Pharmacol, 2011,672（1⁃3）:1⁃8. doi: 10.1016/j.ejphar.2011.08. 047.
［25］	Kurzen H, Kurokawa I, Jemec GB, et al. What causes hidradenitis suppurativa?［J］. Exp Dermatol, 2008,17（5）:455⁃472. doi: 10.1111/j.1600⁃0625.2008.00712_ 1.x.
［26］	van der Zee HH, Jemec GB. New insights into the diagnosis of hidradenitis suppurativa: clinical presentations and phenotypes［J］. J Am Acad Dermatol, 2015,73（5 Suppl 1）:S23⁃S26. doi: 10.1016/j.jaad.2015.07.047.
［27］	Lu L, Lai H, Pan Z, et al. Clinical and histopathological characteristics in patients with scarring folliculitis type of acne inversa［J］. Dermatoendocrinol, 2017,9（1）:e1361575. doi: 10. 1080/19381980.2017.1361575.
［28］	Zouboulis CC, Desai N, Emtestam L, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa［J］. J Eur Acad Dermatol Venereol, 2015,29（4）:619⁃644. doi: 10.1111/jdv.12966.
［29］	Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: Part I: Diagnosis, evaluation, and the use of complementary and procedural management［J］. J Am Acad Dermatol, 2019,81（1）:76⁃90. doi: 10.1016/j.jaad.2019.02. 067.
［30］	Hurley H. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach［M］//Roenigh R, Roenigh H. Dermatologic Surgery. New York: Marcel Dekker, 1989:729⁃739.
［31］	Sartorius K, Lapins J, Emtestam L, et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa［J］. Br J Dermatol, 2003,149（1）:211⁃213. doi: 10.1046/j.1365⁃2133.2003.05390.x.
［32］	Sartorius K, Emtestam L, Jemec GB, et al. Objective scoring of hidradenitis suppurativa reflecting the role of tobacco smoking and obesity［J］. Br J Dermatol, 2009,161（4）:831⁃839. doi: 10. 1111/j.1365⁃2133.2009.09198.x.
［33］	Hessam S, Scholl L, Sand M, et al. A novel severity assessment scoring system for hidradenitis suppurativa［J］. JAMA Dermatol, 2018,154（3）:330⁃335. doi: 10.1001/jamadermatol.2017.5890.
［34］	Amano M, Grant A, Kerdel FA. A prospective open⁃label clinical trial of adalimumab for the treatment of hidradenitis suppurativa［J］. Int J Dermatol, 2010,49（8）:950⁃955. doi: 10. 1111/j.1365⁃4632.2010.04545.x.
［35］	Grant A, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double⁃blind, placebo⁃controlled crossover trial［J］. J Am Acad Dermatol, 2010,62（2）:205⁃217. doi: 10.1016/j.jaad. 2009.06.050.
［36］	Kimball AB, Sobell JM, Zouboulis CC, et al. HiSCR （hidradenitis suppurativa clinical response）: a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo⁃controlled portion of a phase 2 adalimumab study［J］. J Eur Acad Dermatol Venereol, 2016,30（6）:989⁃994. doi: 10.1111/jdv.13216.
［37］	Zouboulis CC, Tzellos T, Kyrgidis A, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System （IHS4）, a novel dynamic scoring system to assess HS severity［J］. Br J Dermatol, 2017,177（5）:1401⁃1409. doi: 10. 1111/bjd.15748.
［38］	Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial［J］. Ann Intern Med, 2012,157（12）:846⁃855. doi: 10.7326/0003⁃4819⁃157⁃12⁃201212180⁃00004.
［39］	Ingram JR, Collier F, Brown D, et al. British Association of Dermatologists guidelines for the management of hidradenitis suppurativa （acne inversa） 2018［J］. Br J Dermatol, 2019,180（5）:1009⁃1017. doi: 10.1111/bjd.17537.
［40］	Alikhan A, Sayed C, Alavi A, et al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management［J］. J Am Acad Dermatol, 2019,81（1）:91⁃101. doi: 10.1016/j.jaad.2019.02.068.
［41］	Zouboulis CC, Bechara FG, Dickinson⁃Blok JL, et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization ⁃ systematic review and recommendations from the HS ALLIANCE working group［J］. J Eur Acad Dermatol Venereol, 2019,33（1）:19⁃31. doi: 10.1111/jdv.15233.
［42］	Gulliver W, Landells I, Morgan D, et al. Hidradenitis suppurativa: a novel model of care and an integrative strategy to adopt an orphan disease［J］. J Cutan Med Surg, 2018,22（1）:71⁃77. doi: 10.1177/1203475417736290.
［43］	Alavi A, Lynde C, Alhusayen R, et al. Approach to the management of patients with hidradenitis suppurativa: a consensus document［J］. J Cutan Med Surg, 2017,21（6）:513⁃524. doi: 10.1177/1203475417716117.
［44］	Gulliver W, Zouboulis CC, Prens E, et al. Evidence⁃based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa［J］. Rev Endocr Metab Disord, 2016,17（3）:343⁃351. doi: 10.1007/s11154⁃016⁃9328⁃5.
［45］	Hunger RE, Laffitte E, Läuchli S, et al. Swiss practice recommendations for the management of hidradenitis suppurativa/acne inversa［J］. Dermatology, 2017,233（2⁃3）:113⁃119. doi: 10.1159/000477459.
［46］	Magalhães RF, Rivitti⁃Machado MC, Duarte GV, et al. Consensus on the treatment of hidradenitis suppurativa ⁃ Brazilian Society of Dermatology［J］. An Bras Dermatol, 2019,94（2 Suppl 1）:7⁃19. doi: 10.1590/abd1806⁃4841.20198607.
［47］	Braunberger TL, Nartker NT, Nicholson CL, et al. Ertapenem ⁃ a potent treatment for clinical and quality of life improvement in patients with hidradenitis suppurativa［J］. Int J Dermatol, 2018,57（9）:1088⁃1093. doi: 10.1111/ijd.14036.
［48］	Maarouf M, Clark AK, Lee DE, et al. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials［J］. J Dermatolog Treat, 2018,29（5）:441⁃449. doi: 10.1080/09546634.2017.1395806.
［49］	Miller I, Lynggaard CD, Lophaven S, et al. A double⁃blind placebo⁃controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa［J］. Br J Dermatol, 2011,165（2）:391⁃398. doi: 10.1111/j.1365⁃2133.2011.10339.x.
［50］	Poveda I, Vilarrasa E, Martorell A, et al. Serum zinc levels in hidradenitis suppurativa: a case⁃control study［J］. Am J Clin Dermatol, 2018,19（5）:771⁃777. doi: 10.1007/s40257⁃018⁃0374⁃5.
［51］	Hotz C, Sbidian E, Ingen⁃Housz⁃Oro S, et al. Thalidomide in severe hidradenitis suppurativa: a therapeutic option［J］. Acta Derm Venereol, 2019,99（12）:1170⁃1171. doi: 10.2340/00015 555⁃3268.
［52］	Iwasaki J, Marra DE, Fincher EF, et al. Treatment of hidradenitis suppurativa with a nonablative radiofrequency device［J］. Dermatol Surg, 2008,34（1）:114⁃117. doi: 10.1111/j.1524⁃4725.2007.34025.x.
［53］	Wilden S, Friis M, Tuettenberg A, et al. Combined treatment of hidradenitis suppurativa with intense pulsed light （IPL） and radiofrequency （RF）［J/OL］. J Dermatolog Treat, 2019:1⁃8（2019⁃10⁃17）. doi: 10.1080/09546634.2019.1677842. https://www.tandfonline.com/doi/full/10.1080/09546634.2019.1677842.
［54］	Mahmoud BH, Tierney E, Hexsel CL, et al. Prospective controlled clinical and histopathologic study of hidradenitis suppurativa treated with the long⁃pulsed neodymium:yttrium⁃aluminium⁃garnet laser［J］. J Am Acad Dermatol, 2010,62（4）:637⁃645. doi: 10.1016/j.jaad.2009.07.048.
［55］	Mordon S. Treating hidradenitis suppurativa with photodynamic therapy［J］. J Cosmet Laser Ther, 2018,20（4）:223⁃228. doi: 10. 1080/14764172.2017.1400169.
［56］	Emtestam L, Lapins J, Sartorius K. Carbon dioxide laser treatment using methylene blue⁃assisted sinus tract identification in hidradenitis suppurativa［J］. Dermatol Surg, 2017,43（4）:604⁃605. doi: 10.1097/DSS.0000000000001068.
［57］	Vekic DA, Cains GD. Hidradenitis suppurativa ⁃ management, comorbidities and monitoring［J］. Aust Fam Physician, 2017,46（8）:584⁃588.

[1]	侯晓媛吴南辉徐明圆刘业强. JAK抑制剂巴瑞替尼治疗环状肉芽肿1例[J]. 中华皮肤科杂志, 2024, 57(5): 461-462.
[2]	中华医学会皮肤性病学分会中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病专业委员会 . [开放获取] 中国化学剥脱术临床应用专家共识（公众版2024版）[J]. 中华皮肤科杂志, 2024, 0(5): 20230620-e20230620.
[3]	《乳房外Paget病诊治专家共识（版）》编写委员会专家组. [开放获取] 乳房外Paget病诊治专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 400-408.
[4]	中国医师协会皮肤科医师分会. [开放获取] 慢性瘙痒管理指南（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 387-399.
[5]	中国“一带一路”皮肤病专病联盟分枝杆菌病研究联盟中国麻风防治协会皮肤性病检验与诊断分会. [开放获取] 中国皮肤结核临床诊疗专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 426-434.
[6]	中国医师协会皮肤科医师分会中国中西医结合学会皮肤性病学分会. 红皮病型银屑病诊疗中国专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 409-417.
[7]	中国中西医结合学会皮肤性病学分会真菌学组中国耐药皮肤癣菌病诊治与防控工作组. [开放获取] 中国耐药皮肤癣菌感染诊治与防控专家共识（2024版）[J]. 中华皮肤科杂志, 2024, 57(5): 418-425.
[8]	刘祎曲莹雷文知刘晓刚潘炜华张超. 食盐封包法治疗化脓性肉芽肿25例临床观察[J]. 中华皮肤科杂志, 2024, 0(4): 20230553-e20230553.
[9]	鞠强李嘉祺. [开放获取] 寻常痤疮再认识：从发病机制到治疗策略[J]. 中华皮肤科杂志, 2024, 57(4): 289-294.
[10]	张迪敏曹成周妙妮盛安琪林福全许爱娥. 复方倍他米松注射液联合治疗后进展期非节段型白癜风稳定率及影响因素分析[J]. 中华皮肤科杂志, 2024, 57(4): 350-354.
[11]	何艳艳马骁惠云王雯竹王宝玺曾荣徐浩翔. 基于高通量测序对反常性痤疮中PPAR通路作用的初步探讨[J]. 中华皮肤科杂志, 2024, 57(4): 309-315.
[12]	田静邓思思宋志强. 特应性与非特应性结节性痒疹患者临床特征比较[J]. 中华皮肤科杂志, 2024, 57(4): 331-337.
[13]	宋雨晴杨楠刘琳琳冯子仪韩世新周梅娟. [开放获取] 皮肤磨削术治疗家族性良性慢性天疱疮6例临床观察[J]. 中华皮肤科杂志, 2024, 0(4): 20220278-e20220278.
[14]	岳淑珍树叶罗鸯鸯李珂瑶张圆圆汤建萍韦祝. 奥马珠单抗治疗儿童慢性荨麻疹的疗效和安全性回顾研究[J]. 中华皮肤科杂志, 2024, 57(4): 354-358.
[15]	葛新红马迎东焦亚宁刘玲玲周镁紫薇李博文. 532 nm皮秒激光治疗面部早期脂溢性角化病的疗效和安全性分析[J]. 中华皮肤科杂志, 2024, 57(4): 359-362.

[开放获取] 中国反常性痤疮/化脓性汗腺炎诊疗专家共识（2021版）

Diagnosis and treatment of acne inversa/hidradenitis suppurativa in China: an expert consensus statement （2021 version）

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 57

相关文章 15

Metrics

本文评价

推荐阅读 10